SELLAS Life Sciences Group (SLS) shares fell 14% in recent Thursday trading after the company announced an independent committee's interim analysis of the phase 3 trial of galinpepimut-S for acute myeloid leukemia.

Intraday volume topped 26 million shares versus the daily average of 1.3 million.

Select blinded data showed that less than half of the enrolled patients were confirmed deceased about 10 months after the enrollment's completion and an approximate median follow-up of 13.5 months, suggesting a pooled median survival of over 12 months, the company said Thursday in a statement.

That compares with the expected survival of about six months in a similar patient population, the company said.

The trail data demonstrated "preliminary signals of effectiveness," allowing the trial to continue without modifications, the company said.

The interim analysis was triggered by the trial reaching 60 deaths in the study population, the company said.

The final analysis of data from the phase 3 trial probably will be conducted this year after 80 deaths, the company said.

Price: 0.9850, Change: -0.1550, Percent Change: -13.5695